Genmab — Maj 2018
-
Du har ret Solsen....meeeen det er godt MED penge og sommervejr...go`weekend til alle!
-
-
-
nej, jeg kender kun denne https://oasm.finanstilsynet.dk/dk/soegeresultat.aspx?t=Genmab for danske, som du vist også bruger
-
God morgen.:-)
-
Jeg kan godt bruge mange flere spørgsmål til Q&A på onsdag.
-
God morgen
-
Integrative analysis reveals CD38 as a therapeutic target for plasma cell-rich pre-disease and established rheumatoid arthritis and systemic lupus erythematosus.
Most importantly, our data show for the first time that daratumumab effectively depletes plasma cells/plasmablasts in PBMC from patients with SLE and RA in a dose-dependent manner ex vivo.
http://www.ncbi.nlm.nih.gov/pubmed/29720240 -
Daratumumab, lenalidomide, and dexamethasone in East Asian patients with relapsed or refractory multiple myeloma: subgroup analyses of the phase 3 POLLUX study.
The efficacy and safety profiles of targeted anticancer therapies in East Asian patients may differ from those of the overall study populations in clinical trials14,15. To understand the impact of DRd vs. Rd in the East Asian patient population, we performed subanalyses of POLLUX data to evaluate the efficacy and safety of DRd vs. Rd in -
...East Asian (Japanese, Korean, and Taiwanese) patients as well as in only Japanese patients.
Reslutatet var enslydende med POLLUX generelt.
East Asian (Japanese, Korean, and Taiwanese) patients as well as in only Japanese patients.
Reslutatet var enslydende med POLLUX generelt.
East Asian (Japanese, Korean, and Taiwanese) patients as well as in only Japanese patients.
Reslutatet var enslydende med POLLUX generelt.
http://www.ncbi.nlm.nih.gov/pubmed/29712896 -
Immunomodulatory effects of CD38-targeting antibodies. God indblik i den avancerede molekylære mekanisme + nye muligheder.
https://sci-hub.hk/10.1016/j.imlet.2018.04.005 -
Durable treatment response of relapsing CNS plasmacytoma using intrathecal chemotherapy, radiotherapy, and Daratumumab
Although the therapy of CNS EMM is dif- ficult, the present case illustrates that a durable response (19 months) can be achieved by using systemic daratumumab therapy, IT chemotherapy, and craniospinal radiotherapy, which compares favorably to the reported literature.https://sci-hub.hk/10.1002/ccr3.1451 -
Responses to daratumumab in AL (immunoglobulin light chain) amyloidosis have also been reported.5 In our patient with POEMS syndrome, the remarkable response to daratumumab and lenalidomide suggests that this combination is a promising nontoxic alternative to ASCT that warrants exploration in POEMS syndrome.
https://www.mayoclinicproceedings.org/article/S0025-6196(18)30098-3/fulltext -
Tusinde tak for masser af spændende læsestof.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind